Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selonsertib in NASH with Bridging Fibrosis
NCT03053050Phase 3Terminated
- Sponsor
- Gilead Sciences
- Start
- Feb 2017
- Primary completion
- Jun 2019
- Modality
- Small Molecules
- Countries
- 27
01
Overview
Phase 3, randomised, double-blind trial of selonsertib in Nonalcoholic steatohepatitis (NASH) (3 arms), sponsored by Gilead Sciences. Primary endpoints: Percentage of Participants Who Achieved a >= 1-Stage Improvement in Fibrosis Without Worsening of NASH at 48 weeks and Event-Free Survival (EFS) as Assessed by Time to First Clinical Event at 240 weeks. Started Feb 2017; status: terminated.
02
Drugs
selonsertib
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT03053050.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03053050.